Overexpression of bcl-2 delays the onset of apoptosis in lymphohematopoietic cells. We measured levels of bcl-2 protein in normal and leukemic human B-cell progenitors with a specific monoclonal antibody and flow cytometry. Normal immature B cells had low levels of bcl-2 protein; the intensity of fluorescence, expressed as molecules of solublefluorochrome per cell, within CD1 O+ cells was 3,460 f 1,050 (mean f SD; 5 samples). In 1 6 cases of B-lineage acute lymphoblastic leukemia (ALL), cells had levels of bcl-2 that were strikingly higher than those of their normal Counterparts (33,560 f 14,570; P < .001 by t-test analysis). We next investigated whether the intensity of bcl-2 expression correlated with the resistance of immature B cells to in vitro culture. In 12 cases of B-lineage ALL, the cells recovered after 7 days of culture on allogeneic bone marrow stromal layers were 69% to 178% (median, 95.5%) of those originally seeded. Prolonged survival of leukemic HE PRODUCT OF the human gene bel-2 antagonizes
T the triggering of programmed cell death ("apoptosis"). Thus, overexpression of bel-2 delays apoptosis in factor-dependent cell lines cultured under suboptimal conditions2,' and in cortical thymocytes exposed to glucocorticoid, radiation, and CD3 antibodies. 6 It has been postulated that abnormally high levels of bel-2 at critical stages of differentiation may favor the development of n e o p l a~i a .~.~-~-'~ This concept is supported by the observation of discrepancies in bcl-2 protein expression between follicular B-cell non-Hodgkm's lymphoma (NHL) cells, which exhibit high levels of bcl-2, and their normal counterparts, proliferating germinal center cells, which appear to be bel-2 negative and are susceptible to apoptosis during the selection processes that occur during immune response in the peripheral lymphoid organs.' '-I4 Abnormally high expression of bcl-2 by these cells may suppress apoptosis, leading to the survival of inappropriate clones. In NHL, increased bcl-2 synthesis results from a chromosomal translocation, t( 14 ; 18) , that brings the bel-2 gene on chromosome 18 at q2 1 next to the Ig heavy chain locus ( 14q32).I5-'* However, abnormally high levels of the bcl-2 protein have also been observed in rare cases of NHL that lack either karyotypic or molecular evidence of bel-2 gene rearrangement,'' suggesting that other mechanisms may induce overexpression Whether malignancies beyond NHL overexpress bel-2 is still unclear. Because the bcl-2 protein is widely distributed among different normal lymphohematopoietic cells and is found in lymphoid, myeloid, and erythroid lineages,' ',I2 techniques for detecting bel-2 expression at the single cell level are needed to assess the amounts of this protein in normal versus malignant cells. So far, attempts to quantitate bel-2 expression have generally relied on measurements of the abundance of messenger RNA (mRNA) transcripts, an approach that is not suited for comparative investigations with small cell subpopulations.
We used flow cytometric techniques and a monoclonal antibody (MoAb) that recognizes the human bel-2 protein' ' of bel-2.
cells in vitro was observed even in the absence of stromal layers in 6 of these 1 2 cases; the intensity of bcl-2 protein expression in these cases was 45,000 f 13,270, compared with 21,500 f 7,260 in the 6 cases in which greater than 99.5% of cells rapidly died by apoptosis under the same culture conditions (P = .003). Five immature B-cell lines, continuously growing in the absence of stroma, had the highest bcl-2 expression (79,400 f 20,330 
MATERIALS AND METHODS

Cells.
Bone marrow (BM) samples were taken from eight healthy BM transplantation donors, aged 2 to 23 years (median, 11 years). Normal peripheral blood (PB) samples were collected from five healthy 22-to 37-year-old volunteers. Tonsil samples were from three children undergoing routine tonsillectomies; cell suspensions were prepared with forceps and surgical blades. Leukemic marrow or PB samples (patients I and 6, Table I ) were collected at diagnosis from 16 patients, aged I to 12 years (median, 6 years), with B-lineage ALL. In all cases, greater than 90% of the blasts expressed CD22, HLA class I1 antigens, and terminal deoxynucleotidyl transferase (TdT) (Table I) . Samples from patients 2 through 4, 9, 10, and 12 were included in a previous p~b l i c a t i o n .~~ The Institutional Review Board approved these studies and informed consent was obtained from patients and their guardians. Mononuclear cells were collected after centrifugation on a density gradient (Lymphoprep; Nycomed, Oslo, Norway) and washed three times in phosphate-buffered saline (PBS). in size to the b d 2 a protein, in immunoblots under both reducing and nonreducing conditions." Staining with this reagent is confined to the cytoplasm. In the present study, antibody reactivity was analyzed with cytocentrifuge preparations as well as by flow cytometry using suspensions of permeabilized cells. The former were prepared with a Cytospin I1 Shandon centrifuge (Shandon, Runcorn, UK), air dried, fixed in acetone:methanol 1: 1 for 15 minutes at 4"C, and labeled with antibodies and second-layer antisera. In these experiments, anti- Table 2 ) and tonsil (bottom panels) samples were studied. Antibody labeling of cells with "lymphoid" morphology is illustrated, after appropriate "gating" using the forward versus 90" light scatter dot plot. Most CD10+ in BM and tonsil show weak or negative bcl-2 staining (see text).
bcl-2 was used in conjunction with a rabbit anti-TdT antiserum (Supertech Inc, Bethesda, MD) and species-specific second-layer antisera conjugated to fluorescein isothiocyanate (FITC) and tetramethyl rhodamine (TRITC). Slides were viewed with a Zeiss fluorescence microscope equipped with blocking filters for FITC and TRITC. For cell suspension staining, mononuclear cells were resuspended in PBS to a final concentration of 2 X 107/mL. Cell fixation and permeabilization were performed as described by Schmid et al?' using 0.25% para-formaldehyde and 0.2% Tween 20, respectively. Doublecolor immunofluorescence staining was performed by labeling unpermeabilized cells with goat antihuman-IgM conjugated to phycoerythrin (PE; Southern Biotechnology Associates [SBA], Birmingham, AL), CD 19 (AB I ; IgM class; obtained from the IVth Conference on Leucocyte Differentiation Antigens), or CDlO (IgM class; Clonab, Biotest Ag, Dreieich, Germany). The latter reagents were followed by goat antiserum to mouse IgM PE. After cell permeabilization, anti-bcl-2 MoAb (IgG class) was added, followed by goat antimouse IgG FITC (both second-layer reagents were from Jackson Immunoresearch Laboratories, Inc, West Grove, PA).
To study bel-2 expression during the different phases of the cell cycle, we labeled BM mononuclear cells with CDlO and goat-antimouse IgM PE and permeabilized them as above. The cells were then stained with anti-bel-2 and goat-antimouse IgG FITC postfixed with 0.5% paraformaldehyde for IO minutes, treated with DNAsefree RNAse (Boeringer Mannheim, Indianapolis, IN; 11.25 Kunitz units), and labeled with 7-actinomycin D (7-AAD; 25 pg/mL; Sigma, St Louis, MO), for at least 30 minutes." To investigate Nalm6 cells, we omitted surface staining and labeled the DNA with propidium iodide (PI; IO pg/mL; Calbiochem, La Jolla, CA). Antibody controls for surface antigens and bcl-2 staining were unreactive MoAbs of The synthetic peptide GAAPAPGIFSSQPG, analogous to that used for immunization, was synthesized with an Applied Biosystems Peptide Synthesizer 430A (Foster City, CA) with Fmoc HOBt/NMP chemistry.
Determination of DNA fragmentation and counting of nonupoptotic cells. DNA fragmentation was assessed by agarose gel electrophoresis as described in detail elsewhere.20 Nonapoptotic cells were counted by a flow cytometric technique, as follows. Cells harvested as above after different times in culture were washed three times in PBS containing 0.2% bovine serum albumin and 0.2% sodium azide (PBSA). An aliquot of the suspension was incubated with CD 19 FITC MoAb or with a combination of CD19 conjugated to peridin chlorophyl protein (Leu12 PerCP BD), CD34 PE (BD), and a mixture of goat- Abbreviation: NT, not tested.
antihuman Ig light-chain antisera conjugated to FITC (SBA). After two washes in PBSA, the cells were resuspended in 0.5% paraformaldehyde and analyzed with a FACScan and the Lysis I1 software (BD). In each case, we designed "gates" around the area of the lightscatter dot plot where the vast majority of leukemic cells were found and used these to calculate the number ofcells with the predetermined light-scattering properties present in the culture. These numbers were then corrected according to the percentage of cells expressing different antigens present in the sample studied?'
RESULTS
bcl-2 expression during normal B-cell diferentiation. The overall expression of bcl-2 within CD19+ cells (including all B-lineage cells) in five normal BM samples was low (MESF, 2,600 to 3,800; median, 3,000; Table 2 and Fig 1) . The percentage of CDIO+ immature B cells with levels of bcl-2 above control ranged from 9.1% to 30.1%; the intensity of bcl-2 expression within the entire CDIO+ cell population ranged from 2,600 to 5,000 (median, 2,900; Table 2 and Fig I) . The expression of bcl-2 within BM sIgM+ lymphocytes was heterogeneous (Table 2 ). In three of five samples, the vast majority of sIgM+ cells had low bcl-2 MESF values ( I ,600, 1,800, and 2,000). By contrast, in the two remaining samples, staining of sIgM+ cells for bcl-2 yielded a biphasic histogram corresponding to two separate cell populations. The MESF in the cells with low bcl-2 expression was 1,600 in one sample and 2,000 in the other; in the cells with high bcl-2 expression, the values were 23,000 and 32,000, respectively ( Table 2 ). The expression of bcl-2 in the latter cells was similar to that seen in B lymphocytes from five PB samples, in which greater than 90% of slgM+ cells expressed bcl-2 with overall MESF values of 25,000 to 36,000 (median, 30,000). Similar observations were made when the antihuman IgM reagent was substituted with a mixture of anti-r and anti-X human lightchain antibodies (data not shown).
When studied by fluorescence microscopy, 42% to 65% of TdT+ progenitor cells had detectable staining with anti-bcl-2. These cells were heterogeneous in size, with some appearing as small lymphoid cells and others being large blasts with nucleoli.
Expression of bcl-2 protein was also studied in three tonsil samples, in which 16.4%, 19.1%, and 44.1% of cells were CDlO+; 89.5%, 72.9%, and 84.1% ofthese cells had weak or absent bcl-2 expression, with overall MESF values of 5,000, 5,800, and 3,500, similar to that observed in CDlO' cells in BM ( Table 2 and Fig 1) . Tonsillar CDlO+ cells include reactive germinal center cells24 and these data are in line with the observation that most of these cells have undetectable levels of bcl-2 on immunohistologic examination."*12
Increased bcl-2 expression in B-lineage ALL and immature B-cell lines. Sixteen samples of B-lineage ALL and five continuously growing B-lineage cell lines were also studied. In all leukemic cases, greater than 80% of cells showed bcl-2 staining higher than the highest intensity observed with the isotype-matched negative control antibody; the MESF ranged from 14,000 to 68,000 (Table 3) . Cell staining was completely abolished when the anti-bcl-2 antibody was preincubated with the peptide used for immunization. Thus, leukemic cells expressed strikingly higher levels of bcl-2 than did their normal CDlO+ counterparts (mean MESF +-SD of 33,560 f 14,570 v 3,460 f 1,050; P < .001 by t-test). However, the intensity of bcl-2 in cell lines (79,400 f 20,330) was even higher than the value for the ALL cases (P < .001; Table 3 ).
Expression of bcl-2 by leukemic cells did not correlate with the patients' clinical features at diagnosis. The initial white blood cell (WBC) count in this series ranged from 6.0 to 870 X 109/L, without any linear relationship to bcl-2 expression (r = -.164; Tables 1 and 3) .
We also attempted to relate the intensity of bcl-2 expression to the leukemic cell karyotype, which was available for 12 cases. None of the cases had metaphases with the t ( 14; 1 8) , the translocation found in the majority of cases of follicular B-cell NHL in adults, or abnormalities involving I8q2 1 (Table l). fragmented DNA Lerikcmic Ivtnphohlasts srrrviw lonjyr lhan normal l3-cell progenitors. In a previous study, we demonstrated that allogeneic BM stromal feeder layers prcvent apoptosis and support optimal survival of leukemic lymphoblasts in vitro."' In the present study, we compared the ability of these feeder layers to maintain normal and leukemic B-cell progenitors in vitro. Twelve of the 16 cases of B-lineage ALL included in this study were tested. Cell numbers were investigated at the beginning and after 7 days of culture and the percentage of cells recovered was 68% to 178% (median. 95.5%) of those originally seeded. By contrast. the number of normal CDI 9' cells considerably decreased under identical culture conditions and less than one-third were recovered after 7 days in three samples studied (Tablc 4). Cell loss was severe within the rapidly dividing CD19'. slg-immature B-cell compartment. Triple-color analysis by flow cytometry showed that the most immature CD19' cells, identified by the expression of CD34, were also the cells disappearing most rapidly (Table  4) .
bcl-2 eypression " x c r t e y with siindval rcqriirements of krikcmic cell.^. A furthcr hetcrogencity in cells life span associated with diffcrent expression of Id-2 protein was found within the B-lineage ALL cases. We previously observed that in some cases a substantial proportion of cells can be recovered even after prolonged periods of culture without stromal cells." Phenotypic or karyotypic markcrs that would distinguish cases requiring stromal support from those capable of surviving in serum-free medium have not been identified. In 6 of the 12 cases included in the present study (nos. 9. IO. 12. 13, 15. and 16). no signs of apoptosis were seen after 72 hours of culture in the absence of stroma (Fig 2) . The mean 2 SD MESF of hcl-2 in these cases was 45,000 2 13,270. In intact DNA the other six cases (nos. I through 4,6, and 7). signs of massive apoptosis were evident within 3 days of culture in serum-free medium (Fig 2) . The mean ? SD MESF of hcl-2 in these cases was significantly lower than in the previous group (2 1,500 +. 7,260: P = .003). By contrast, the expression of for CDl9). In all cases in which signs of rapid apoptosis were observed, less than 0.5% of the cells were viable after 7 days of culture. By contrast, in the cases with higher bel-2 protein expression, a proportion of nonapoptotic CD 19' cells (20% to 95% of the original population) persisted after 7 days of culture. However, the percentage of cells recovered (95% in patient 9; 90% in patient 10; 55% in patient 12; 20% in patient 13; 32% in patient 15; 46% in patient 16) did not have a linear relation to the intensity of bel-2 expression, suggesting that other factors had influenced the expansion of ALL cells.
The percentage of cells in S phase at diagnosis ranged from 1.4% to 22.6% among the 16 cases of ALL; these values did not strongly correlate with bel-2 expression (r = .146; Tables I  and 3 ). To investigate whether the expression of bel-2 changes as cells progress through the cell cycle, we simultaneously labeled a pre-B-leukemia cell line, Nalm 6, for bel-2 and DNA content. Normal B-cell progenitors from two marrow samples were also labeled by this method; the immature B cells were recognized by CDlO labeling, with triple-color immunofluorescence used to study the samples. The expression of bel-2 remained constant in both leukemic and normal progenitor cells throughout the different phases of the cell cycle (Fig 3) .
Constant bcl-2 expression during the cell cycle.
DISCUSSION
In this study of the expression of the bcl-2 protein among normal and leukemic human B cells, we showed that bel-2 expression is low in immature B-cell precursors, which are, in this respect, similar to reactive germinal center cells.Il,l2 Thus, during B-cell differentiation, levels of bel-2 protein are at their lowest in B-lineage cells that proliferate in central and peripheral lymphoid organs. It is unlikely that the fluctuations of bel-2 levels we observed are related to cell cycle because continuously growing cell lines had the highest levels of bel-2 protein and cells in S, G2, or M phase did not have lower levels of bcl-2 expression than cells in GO or GI. In addition, bel-2 expression in B-lineage ALL did not correlate with the proportion of cells in S phase.
Low expression of bcl-2 in germinal center cells could be instrumental in allowing selection mechanisms based on affinity for antigen to operate through apoptosis. I Immature B-cell progenitors are also likely to undergo apoptosis during normal development because rearrangements of Ig genes may be unsuccessful in a large proportion of cells25-2s; it has been postulated that less than 10% of these progenitors mature to sIg+ B lymphocyte^.^' Low levels of bel-2 expression at this stage of differentiation may be advantageous, facilitating the swift demise of ineffective progenitor cells. The rapid disappearance of these cells was observed when purified normal BM B cells were cultured under conditions that can support the expansion of leukemic B cells for several months. Only a fraction of CD19+, sIg-cells could be recovered after 7 days of culture despite the presence of stromal feeder layers. It is unlikely that the disappearance of these rapidly proliferating3' progenitor cells was entirely due to cell maturation because the numbers of sIg+ lymphocytes in our cultures did not increase. It is possible that improved culture conditions and the addition of cytokines may allow greater numbers of normal immature B cells to survive and differentiate in ~u l t u r e~~,~~ (A. Manabe and D. Campana, unpublished observations). However, in the culture system used in this study, they appear to be more vulnerable than their neoplastic counterparts.
High levels of bel-2 protein in leukemic cells may lead to a prolonged lifespan, and lend a growth advantage to these cells despite their lower proliferation rate.30 BM-derived stromal cells support long-term culture of most ALL samp l e~.~' ,~~
In the absence of stromal feeder layers, cultured cells rapidly die by apoptosis in most case^.^',^^ In this respect, these cases of ALL resemble factor-dependent hematopoietic cell lines cultured under suboptimal ~o n d i t i o n s . ' -~.~~.~~ However, in a proportion of ALL cases, delayed onset of apoptosis and prolonged survival of cells in vitro is seen in the absence of stromal feeder layers. In this study, we observed that these latter cases had a higher bel-2 expression. These results are consistent with experiments showing that transfection of bcl-2 in cytokine-dependent cell lines retards the initiation of cell death in unfavorable culture conditions.1-3
Our findings support the concept that, during normal Bcell development, bcl-2 protein levels are low at stages of differentiation when apoptosis may be physiologically triggered (eg, in cells that have failed to rearrange Ig genes, and in antigen-responding clones with low affinity for the antigen). Overexpression of bel-2 in cells susceptible to apoptosis is likely to favor the survival of immunologically inadequate ~e l l s .~*~~~~~' A consequence of high bel-2 expression in B-cell progenitors would be the prolonged survival of cells with nonproductive Ig heavy-or light-chain gene rearrangement, a characteristic of virtually all cases of B-lineage ALL.26,37 While in NHL, the t( 14;18) abnormality leads to overexpression of b~l -2 , '~3~~-' * we could not find karyotypic evidence of bel-2 gene rearrangement in the B-lineage ALL cases. Structural abnormalities of chromosome 18q2 1 are extremely rare in childhood ALL, and only two children with NHL and the t( 14;18) have been reported in the literat~re.~' The mechanism for increased expression of bel-2 in other cases of ALL remains to be identified.
In conclusion, the results of this study suggest that regulation of bel-2 expression plays an important role in the development of human B cells and that abnormal gene expression may contribute to leukemogenesis by prolonging the life span of progenitor cells unable to further differentiate. In addition, overexpression of bel-2 may facilitate the expansion of the leukemic clones outside the BM microenvironment. This study cannot address whether the expression of bel-2 correlates with treatment outcome in ALL, as all patients remain in continuous remission with a relatively short followup (3 to 46 months; median, 9 months). Further studies may disclose the value of bcl-2 expression as a prognostic indicator and its association with clinical features of ALL, such as occurrence of extramedullary relapse and resistance of leukemic cells to drugs. For personal use only. on January 25, 2018. by guest www.bloodjournal.org From
